Stocks · Health care · Biological Products, (No Diagnostic Substances)

Biogen

BIIB Clue Score50

United States Fiscal year ends December CIK 0000875045 Results filed 28 Oct 2026

Add to watchlist

What the insiders did Net buying

By person

41 insiders · 73 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Alexander J Denner

Director

$90.83M (11)

—

+$90.83M

658,099

0.4454%

$132.25M

+106.9%

Paul J Clancy

Executive VP and CFO

—

$5.75M (2)

−$5.75M

10,813

0.0073%

$2.17M

−59.8%

Alfred Sandrock

Head of Research & Development

—

$5.67M (8)

−$5.67M

10,169

0.0069%

$2.04M

+17.6%

Robert W Pangia

Director

—

$5.54M (3) scheduled

−$5.54M

20,632

0.0140%

$4.15M

+23.9%

Susan H Alexander

EVP Chief Legal Officer

—

$5.21M (3)

−$5.21M

61,889

0.0419%

$12.44M

+94.4%

Michel Vounatsos

Chief Executive Officer

$2.77M (5)

—

+$2.77M

67,261

0.0455%

$13.52M

+12,421%

Ginger Gregory

EVP, Human Resources

—

$2.49M (2)

−$2.49M

22,359

0.0151%

$4.49M

+3,341%

Stephen A Sherwin

Director

—

$2.03M (3) scheduled

−$2.03M

15,193

0.0103%

$3.05M

+236.9%

Priya Singhal

Head of Development

—

$2.02M (16) scheduled

−$2.02M

8,043

0.0054%

$1.62M

+327.6%

Chirfi Guindo

Head of Glob Prod Strat & Com

—

$1.36M (1)

−$1.36M

7,364

0.0050%

$1.48M

—

Brian S Posner

Director

—

$684.97K (3)

−$684.97K

8,175

0.0055%

$1.64M

+31.1%

Michael D Ehlers

EVP, Research and Development

—

$350.00K (1)

−$350.00K

8,025

0.0054%

$1.61M

+140.3%

Rachid Izzar

Head of Global Product Strat.

—

$300.11K (1) scheduled

−$300.11K

11,011

0.0075%

$2.21M

—

Jesus B Mantas

Director

$239.77K (1)

—

+$239.77K

11,263

0.0076%

$2.26M

—

Lloyd Minor

Director

—

$239.75K (2) scheduled

−$239.75K

2,689

0.0018%

$540.38K

—

Caroline Dorsa

Director

$151.56K (1)

—

+$151.56K

31,002

0.0210%

$6.23M

+81.1%

Eric K Rowinsky

Director

$101.26K (1)

—

+$101.26K

25,844

0.0175%

$5.19M

+97.4%

Adriana Karaboutis

EVP, Tech, Bus. Sol & Corp Aff

—

$14.23K (1)

−$14.23K

8,752

0.0059%

$1.76M

+14.5%

Nicole Murphy

Head of Pharm Ops and Tech

$585.11 (1)

—

+$585.11

19,611

0.0133%

$3.94M

+1,067%

Christopher Viehbacher

President and CEO

—

—

—

29,924

0.0203%

$6.01M

+327.5%

Michael R. McDonnell

EVP, Chief Financial Officer

—

—

—

24,341

0.0165%

$4.89M

—

Richard Mulligan

Director

—

—

—

15,099

0.0102%

$3.03M

+68.3%

Nancy Leaming

Director

—

—

—

13,763

0.0093%

$2.77M

+52.8%

Robin Kramer

Chief Financial Officer

—

—

—

11,472

0.0078%

$2.31M

+2,905%

William A Hawkins

Director

—

—

—

10,365

0.0070%

$2.08M

—

Stelios Papadopoulos

Director

—

—

—

10,095

0.0068%

$2.03M

—

Lynn Schenk

Director

—

—

—

9,032

0.0061%

$1.82M

+51.2%

Maria C Freire

Director

—

—

—

8,820

0.0060%

$1.77M

—

Paul McKenzie

EVP Pharmaceutical Oper & Tech

—

—

—

7,235

0.0049%

$1.45M

+1,697%

Kenneth DiPietro

EVP Human Resources

—

—

—

7,177

0.0049%

$1.44M

+82.3%

Susan Langer

Director

—

—

—

6,634

0.0045%

$1.33M

+1,345%

Adam Keeney

Head of Corporate Development

—

—

—

6,365

0.0043%

$1.28M

—

Monish D Patolawala

Director

—

—

—

5,215

0.0035%

$1.05M

—

Alphonse Galdes

EVP Pharmaceutical Oper & Tech

—

—

—

5,064

0.0034%

$1.02M

+213.3%

Gregory F Covino

VP, Chief Accounting Officer

—

—

—

4,744

0.0032%

$953.43K

+51.7%

Jane Grogan

Head of Research

—

—

—

4,408

0.0030%

$885.83K

—

Menelas N Pangalos

Director

—

—

—

3,875

0.0026%

$778.72K

—

Jeffrey D Capello

EVP & Chief Financial Officer

—

—

—

3,118

0.0021%

$626.59K

—

William D /Ca/ Jones

Director

—

—

—

2,145

0.0015%

$431.06K

—

Sean Godbout

Chief Accounting Officer

—

—

—

1,459

0.0010%

$293.20K

+153.7%

Daniel Karp

EVP, Corporate Development

—

—

—

930

0.0006%

$186.97K

+636.1%